Zynerba Pharmaceuticals (ZYNE) Prices 3M Common Stock IPO at $14/Share
Get Alerts ZYNE Hot Sheet
Join SI Premium – FREE
Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Entrata (ENT) files for proposed IPO
- Silver Storm closes $21M private placement with second tranche
- DeFi Development Corp. plans $20M preferred stock offering
Create E-mail Alert Related Categories
Corporate News, IPOsRelated Entities
Piper Jaffray, Jefferies & Co, Canaccord Genuity, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share